RNAi Drug Delivery Market is estimated to increase at a growth rate of 17.5% CAGR over the forecast period from 2024 to 2030.
The global RNAi Drug Delivery Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Technology (Nanoparticle drug delivery, Pulmonary drug delivery, Nucleic acid drug delivery, Aptamer drug delivery), By Application (Infectious diseases, Oncology, Cardiology, Neurology, Others).
An Introduction to RNAi Drug Delivery Market in 2024
The RNA interference (RNAi) Drug Delivery Market encompasses delivery technologies, carriers, vectors, and formulations used to transport small interfering RNA (siRNA) and microRNA (miRNA) molecules into target cells for gene silencing, therapeutic gene modulation, and precision medicine applications. RNAi-based therapies hold promise for treating various diseases, including cancer, genetic disorders, viral infections, and neurological conditions, by regulating gene expression and cellular pathways. Market trends include lipid nanoparticles, polymer-based carriers, viral vectors, exosomes, and nanoparticle conjugates as RNAi delivery platforms, along with advancements in delivery strategies for systemic, targeted, and cell-specific RNAi therapeutics delivery.
RNAi Drug Delivery Market Competitive Landscape
The global RNAi Drug Delivery Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, RNAi Drug Delivery Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the RNAi Drug Delivery Industry include- Alnylam Pharmaceuticals Inc, Arrowhead Pharmaceuticals Inc, Bayer AG, Benitec Biopharma Inc, BioNTech SE, Bristol Myers Squibb Co., CureVac AG, e therapeutics plc, F. Hoffmann La Roche Ltd, Novartis AG, Novo Nordisk AS, Phio Pharmaceuticals, Sanofi SA, Silence Therapeutics plc, Silenseed Inc, siRNAgen Therapeutics Corp, Sirnaomics Inc, Sylentis S.A., Thermo Fisher Scientific Inc.
RNAi Drug Delivery Market Trend: Advancements in Delivery Systems
Within the RNAi Drug Delivery market, a notable trend is the continuous advancements in delivery systems. Innovations such as nanoparticle-based carriers, lipid-based formulations, and targeted delivery mechanisms are enhancing the efficiency and specificity of RNAi therapeutics, driving significant interest from pharmaceutical companies and researchers.
RNAi Drug Delivery Market Driver: Demand for Targeted and Personalized Therapeutics
The primary driver for the RNAi Drug Delivery market is the increasing demand for targeted and personalized therapeutics. RNA interference holds immense potential for treating various diseases by precisely silencing specific genes, thereby addressing the underlying molecular mechanisms. As the focus shifts towards personalized medicine, the need for effective RNAi drug delivery systems intensifies.
RNAi Drug Delivery Market Opportunity: Development of Non-Invasive Delivery Methods
An opportunity exists in the development of non-invasive RNAi drug delivery methods that can bypass biological barriers such as the blood-brain barrier or efficiently target specific tissues without invasive procedures. Investing in research to improve delivery efficiency, reduce off-target effects, and enhance patient compliance could unlock new avenues for RNAi therapeutics and expand market reach.
RNAi Drug Delivery Market Share Analysis: Nanoparticle Drug Delivery is the fastest growing market segment over the forecast period to 2030
Nanoparticle drug delivery emerges as the fastest-growing segment in the RNAi drug delivery market. Nanoparticles offer unique advantages for delivering RNAi therapeutics, including enhanced stability, prolonged circulation time, targeted delivery, and reduced off-target effects. With their small size and versatile surface properties, nanoparticles can encapsulate RNAi molecules, protect them from degradation, and facilitate their specific delivery to target cells or tissues. This targeted delivery capability is particularly crucial for RNAi therapies aimed at treating various diseases, including infectious diseases, oncology, cardiology, neurology, and others. Moreover, advancements in nanoparticle synthesis techniques and surface modification strategies have enabled the development of more efficient and biocompatible RNAi delivery systems. As a result, nanoparticle-based RNAi drug delivery holds immense promise for revolutionizing the treatment landscape across a wide range of therapeutic areas, driving its rapid growth within the market.
RNAi Drug Delivery Market Segmentation
By Technology
Nanoparticle drug delivery
Pulmonary drug delivery
Nucleic acid drug delivery
Aptamer drug delivery
By Application
Infectious diseases
Oncology
Cardiology
Neurology
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
RNAi Drug Delivery Companies
Alnylam Pharmaceuticals Inc
Arrowhead Pharmaceuticals Inc
Bayer AG
Benitec Biopharma Inc
BioNTech SE
Bristol Myers Squibb Co.
CureVac AG
e therapeutics plc
F. Hoffmann La Roche Ltd
Novartis AG
Novo Nordisk AS
Phio Pharmaceuticals
Sanofi SA
Silence Therapeutics plc
Silenseed Inc
siRNAgen Therapeutics Corp
Sirnaomics Inc
Sylentis S.A.
Thermo Fisher Scientific Inc
* List not Exhaustive
Reasons to Buy the RNAi Drug Delivery Market Study
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the RNAi Drug Delivery Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the RNAi Drug Delivery Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 RNAi Drug Delivery Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global RNAi Drug Delivery Market Size Outlook, $ Million, 2021 to 2030
3.2 RNAi Drug Delivery Market Outlook by Type, $ Million, 2021 to 2030
3.3 RNAi Drug Delivery Market Outlook by Product, $ Million, 2021 to 2030
3.4 RNAi Drug Delivery Market Outlook by Application, $ Million, 2021 to 2030
3.5 RNAi Drug Delivery Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of RNAi Drug Delivery Industry
4.2 Key Market Trends in RNAi Drug Delivery Industry
4.3 Potential Opportunities in RNAi Drug Delivery Industry
4.4 Key Challenges in RNAi Drug Delivery Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global RNAi Drug Delivery Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global RNAi Drug Delivery Market Outlook by Segments
7.1 RNAi Drug Delivery Market Outlook by Segments, $ Million, 2021- 2030
By Technology
Nanoparticle drug delivery
Pulmonary drug delivery
Nucleic acid drug delivery
Aptamer drug delivery
By Application
Infectious diseases
Oncology
Cardiology
Neurology
Others
8 North America RNAi Drug Delivery Market Analysis and Outlook To 2030
8.1 Introduction to North America RNAi Drug Delivery Markets in 2024
8.2 North America RNAi Drug Delivery Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America RNAi Drug Delivery Market size Outlook by Segments, 2021-2030
By Technology
Nanoparticle drug delivery
Pulmonary drug delivery
Nucleic acid drug delivery
Aptamer drug delivery
By Application
Infectious diseases
Oncology
Cardiology
Neurology
Others
9 Europe RNAi Drug Delivery Market Analysis and Outlook To 2030
9.1 Introduction to Europe RNAi Drug Delivery Markets in 2024
9.2 Europe RNAi Drug Delivery Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe RNAi Drug Delivery Market Size Outlook by Segments, 2021-2030
By Technology
Nanoparticle drug delivery
Pulmonary drug delivery
Nucleic acid drug delivery
Aptamer drug delivery
By Application
Infectious diseases
Oncology
Cardiology
Neurology
Others
10 Asia Pacific RNAi Drug Delivery Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific RNAi Drug Delivery Markets in 2024
10.2 Asia Pacific RNAi Drug Delivery Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific RNAi Drug Delivery Market size Outlook by Segments, 2021-2030
By Technology
Nanoparticle drug delivery
Pulmonary drug delivery
Nucleic acid drug delivery
Aptamer drug delivery
By Application
Infectious diseases
Oncology
Cardiology
Neurology
Others
11 South America RNAi Drug Delivery Market Analysis and Outlook To 2030
11.1 Introduction to South America RNAi Drug Delivery Markets in 2024
11.2 South America RNAi Drug Delivery Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America RNAi Drug Delivery Market size Outlook by Segments, 2021-2030
By Technology
Nanoparticle drug delivery
Pulmonary drug delivery
Nucleic acid drug delivery
Aptamer drug delivery
By Application
Infectious diseases
Oncology
Cardiology
Neurology
Others
12 Middle East and Africa RNAi Drug Delivery Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa RNAi Drug Delivery Markets in 2024
12.2 Middle East and Africa RNAi Drug Delivery Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa RNAi Drug Delivery Market size Outlook by Segments, 2021-2030
By Technology
Nanoparticle drug delivery
Pulmonary drug delivery
Nucleic acid drug delivery
Aptamer drug delivery
By Application
Infectious diseases
Oncology
Cardiology
Neurology
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Alnylam Pharmaceuticals Inc
Arrowhead Pharmaceuticals Inc
Bayer AG
Benitec Biopharma Inc
BioNTech SE
Bristol Myers Squibb Co.
CureVac AG
e therapeutics plc
F. Hoffmann La Roche Ltd
Novartis AG
Novo Nordisk AS
Phio Pharmaceuticals
Sanofi SA
Silence Therapeutics plc
Silenseed Inc
siRNAgen Therapeutics Corp
Sirnaomics Inc
Sylentis S.A.
Thermo Fisher Scientific Inc
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
